Picture of Amphastar Pharmaceuticals logo

AMPH Amphastar Pharmaceuticals Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapNeutral

Annual cashflow statement for Amphastar Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line46.51.163.391.4138
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items24.425.710.721.244.7
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-51.79.13-1.92-32.2-24.2
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Net Change in Other Assets & Liabilities
Cash from Operating Activities41.857.39889.2184
Capital Expenditures-41.6-33.9-27.5-24-38.2
Purchase of Fixed Assets
Other Investing Cash Flow Items-8.97-2.56-1.22-8.74-611
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Cash from Investing Activities-50.5-36.4-28.7-32.8-649
Financing Cash Flow Items-0.106-56.2-0.407-25.1
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-3.78-2.25-37-26.4454
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-12.71932.129.7-11.8